Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab report tweaks cut unnecessary antibiotics in ICU patients

NCT ID NCT05989269

Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a simple change in how lab results for respiratory cultures are reported to doctors. For patients on ventilators who did not meet clinical criteria for pneumonia, the lab report noted that the bacteria found might just be harmless colonization. The goal was to see if this would lead to fewer unnecessary antibiotics. The trial involved 161 ICU patients and compared the modified reporting to standard reporting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified lab reporting of respiratory culture results
What this could lead to
If successful, this approach could reduce unnecessary antibiotic use in ICUs, helping to combat antibiotic resistance and improve patient outcomes.
What could go wrong
This is a completed pragmatic trial with 161 participants, so results are limited to this specific setting and may not apply broadly. The intervention only changes how results are reported, not the underlying treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

161 people

The number who actually took part.

Started

Aug 2023

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient located on ICU unit included in the study * Patient is mechanically ventilated * Patient had respiratory culture sent \>48 hours after admission * Patient age ≥ 18 years Exclusion Criteria: * Extra corporeal membrane oxygenation (ECMO) at time of respiratory culture * Heart or lung transplant * Culture rejected by lab per standard lab protocol * Prisoners * Severe immunosuppression as defined by: * \<6 months from solid organ transplant (SOT) OR \<6 months from treatment for acute rejection following SOT * Active treatment for lymphoreticular malignancies * Neutropenic \< 1000 * Receiving lymphodepleting chemotherapy * Allogeneic stem cell transplants \<6 months * Autologous stem cell transplants or chimeric antigen receptor T-cell (CAR-T) therapy \<6 months out * Allogeneic stem cell transplant with graft vs host disease (GVHD) or receiving 2 or more immunosuppressants * Advanced or untreated human immunodeficiency virus (HIV) infection with CD4 \< 200 * Receiving biologics within 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventilator associated pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventilator associated pneumonia

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • University of Maryland

    Baltimore, Maryland, 21201, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23284, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.